Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

Prediction of potent shRNAs with a sequential classification algorithm

(2017) Raphael Pelossof et al.   NATURE BIOTECHNOLOGY

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine

(2017) Chantal Pauli et al.   Cancer Discovery

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2017) Dejan Juric et al.   Cancer Discovery

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

(2016) A. Patnaik et al.   ANNALS OF ONCOLOGY

Ketogenic diet for epilepsy treatment

(2016) Letícia Pereira de Brito Sampaio   ARQUIVOS DE NEURO-PSIQUIATRIA

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer

(2016) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Obesity and Cancer Mechanisms: Cancer Metabolism

(2016) Benjamin D. Hopkins et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer, obesity, diabetes and antidiabetic drugs: is the fog clearing?

(2016) Adi J. Klil-Drori et al.   Nature Reviews Clinical Oncology

Association between markers of glucose metabolism and risk of colorectal cancer

(2016) Jinming Xu et al.   BMJ Open

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

(2016) Sherri Z. Millis et al.   JAMA Oncology

Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet

(2015) Nicholas Douris et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

An emerging role for cytopathology in precision oncology

(2015) Chantal Pauli et al.   CANCER CYTOPATHOLOGY

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

(2014) C. Saura et al.   CLINICAL CANCER RESEARCH

Potential applications for biguanides in oncology

(2013) Michael Pollak   JOURNAL OF CLINICAL INVESTIGATION

Insulin and IGFs in Obesity-Related Breast Cancer

(2013) Valentina Belardi et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

An Optimized microRNA Backbone for Effective Single-Copy RNAi

(2013) Christof Fellmann et al.   Cell Reports

Minireview: IGF, Insulin, and Cancer

(2011) Emily J. Gallagher et al.   ENDOCRINOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Metformin and Other Biguanides in Oncology: Advancing the Research Agenda

(2010) M. Pollak   Cancer Prevention Research

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

(2008) Jing Ma et al.   LANCET ONCOLOGY